The NanoKnife System harnesses the power of Irreversible Electroporation (IRE) to effectively destroy target cells without the use of thermal energy.
PRESERVE is a clinical study, initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), evaluating the use of the NanoKnife System as a focal therapy option for prostate cancer patients. It will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate risk prostate cancer patients.
PRESERVE is a US-based study and is currently enrolling active hospital sites and qualifying patients.
To find out more, email Dr Barqawi directly Al.Barqawi@ucdenver.edu